1. Home
  2. PAHC vs GLUE Comparison

PAHC vs GLUE Comparison

Compare PAHC & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Phibro Animal Health Corporation

PAHC

Phibro Animal Health Corporation

HOLD

Current Price

$34.29

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Logo Monte Rosa Therapeutics Inc.

GLUE

Monte Rosa Therapeutics Inc.

HOLD

Current Price

$15.88

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PAHC
GLUE
Founded
1946
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.7B
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
PAHC
GLUE
Price
$34.29
$15.88
Analyst Decision
Hold
Strong Buy
Analyst Count
4
3
Target Price
$41.25
$32.00
AVG Volume (30 Days)
226.7K
1.5M
Earning Date
05-06-2026
05-08-2026
Dividend Yield
0.91%
N/A
EPS Growth
1883.33
N/A
EPS
1.90
N/A
Revenue
$833,350,000.00
$123,672,000.00
Revenue This Year
$17.03
N/A
Revenue Next Year
$3.82
$2.45
P/E Ratio
$18.68
$72.42
Revenue Growth
4.12
63.54
52 Week Low
$27.83
$4.15
52 Week High
$60.08
$25.77

Technical Indicators

Market Signals
Indicator
PAHC
GLUE
Relative Strength Index (RSI) 54.27 30.37
Support Level $30.55 $14.77
Resistance Level $37.92 $17.99
Average True Range (ATR) 1.26 1.36
MACD 0.15 -1.00
Stochastic Oscillator 56.00 8.16

Price Performance

Historical Comparison
PAHC
GLUE

About PAHC Phibro Animal Health Corporation

Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).

Share on Social Networks: